Shinobi Therapeutics Welcomes Dr. Fischer as New Board Chair
Shinobi Therapeutics has recently announced a significant leadership development by appointing Dr. Laurent Fischer, an esteemed figure in the biotechnology industry, as the Chair of its Board of Directors. This move marks a pivotal point for the company, which is actively engaged in pioneering a groundbreaking class of immune evasive iPSC therapies.
Dr. Fischer’s Extensive Experience
Dr. Fischer brings to Shinobi an impressive background of over 30 years in senior biotechnology leadership. His career is adorned with accomplishments that showcase his expertise in establishing, elevating, and strategically exiting innovative biotech companies. A notable milestone in his career was the acquisition of Adverum Biotechnologies by Eli Lilly, where he played an instrumental role in the development of advanced gene therapies.
Impressive Track Record
His past successes include guiding Tobira Therapeutics to a prosperous IPO and overseeing its remarkable acquisition by Allergan, valuing at $1.7 billion. Dr. Fischer’s leadership at CTI BioPharma, where he oversaw the launch of Vonjo™, ultimately led to a $1.7 billion sale to SOBI, further demonstrating his capacity to navigate complex market landscapes successfully.
Shinobi’s Current Initiatives
Shinobi is gearing up to make significant strides in 2026 by advancing its two pioneering immune evasive iPSC therapies towards clinical trials. The excitement surrounding the company is palpable, especially with its first data presentation planned at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event is set to showcase the innovative research being conducted within the company.
Data Presentation at SITC
The presentation will focus on findings that showcase the capabilities of iPSC-derived CD8 ?? T Cells in mediating tumor destruction. The dataset presented in the poster will elucidate the mechanisms through which these cells, augmented by cytokine armoring, can significantly enhance anti-tumor activity.
Future Directions and Goals
Dr. Fischer expressed his anticipation for this new role at Shinobi Therapeutics, particularly as the company embarks on a path to revolutionize treatment strategies for cancer and autoimmune disorders. His vision is to leverage Shinobi's innovations to address traditional barriers in cell therapy access and cost, which have often limited patient care options.
Funding and Development Plans
The recent appointment of Dr. Fischer coincides with Shinobi's successful funding trajectory, including a robust Series A financing round and a substantial non-dilutive grant from Japan's AMED program. These financial milestones uniquely position the company to further the development of its leading therapies, including NJA-001, focusing on solid tumors, and NJA-201, targeting autoimmune diseases.
About Shinobi Therapeutics
Shinobi Therapeutics is dedicated to addressing the existing gaps in cancer treatment through the development of accessible and effective immune evasive iPSC-derived therapies. The company is rooted in research conducted by noted scientific co-founders at prominent institutions, and their commitment to innovation is supported by recent funding efforts aimed at enhancing therapeutic approaches.
Frequently Asked Questions
What is the significance of Dr. Fischer's appointment?
Dr. Fischer's appointment as Chair of the Board represents a strategic move for Shinobi, leveraging his extensive experience to guide the company towards clinical advancements.
What are immune evasive iPSC therapies?
These therapies are designed to help the immune system evade detection, enhancing the effectiveness of treatments for cancer and autoimmune diseases.
How is Shinobi financed?
Shinobi has secured a $51 million Series A funding in 2023 and a $71 million grant from the AMED program, facilitating its research and development efforts.
What is the focus of Shinobi's upcoming clinical programs?
The company is focused on advancing NJA-001 for solid tumors and NJA-201 for autoimmune diseases, with a goal of clinical trials in 2026.
Where will Shinobi present its first data?
The first data presentation will take place at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, highlighting the company's research on iPSC-derived therapies.
